Subscribe to RSS
DOI: 10.1055/a-0677-7301
Die Effekte nicht-pharmakologischer, gesundheitsfördernder Interventionen bei Menschen mit schweren psychischen Erkrankungen
Ein systematischer LiteraturüberblickThe Impact of Non-Pharmacologic Lifestyle Interventions in People with Severe Mental IllnessA Systematic ReviewPublication History
Publication Date:
10 October 2018 (online)
![](https://www.thieme-connect.de/media/psychiat-praxis/201807/lookinside/thumbnails/785_10-1055-a-0677-7301-1.jpg)
Zusammenfassung
Hintergrund Menschen mit schweren psychischen Erkrankungen sind deutlichen Risiken somatischer Morbidität und erhöhter Mortalität ausgesetzt. Gesundheitsfördernde Interventionen sollen die Risiken dafür reduzieren. Die Arbeit trägt die Evidenz in diesem Bereich zusammen.
Methodik Systematische Suche in Medline, EMBASE, PsycINFO und der Cochrane Library nach Übersichtsarbeiten und RCTs.
Ergebnisse Gesundheitsfördernde Interventionen zeigten nahezu durchweg positive Effekte in Bezug auf die untersuchten Parameter.
Schlussfolgerung Weitere nachhaltige Untersuchungen sind erforderlich.
Abstract
Background In recent years public and research interests focused more and more in lifestyle as a key factor for health. Particularly lifestyle of people with severe mental illness in combination with modifiable risk factors and adverse effects of the antipsychotic medication is especially critical. The present paper investigated the effect of multimodal healthy lifestyle interventions concerning weight and BMI reduction.
Methods We systematically searched electronic databases (Medline, EMBASE, PsycINFO, Cochrane Library) for reviews and RCTs.
Results Six systematic reviews and three single RCTs met inclusion criteria. Analyzed lifestyle interventions, mostly combined approaches of nutrition and sports, showed short and medium term effects in weight and BMI reduction compared with controls.
Conclusion Lifestyle interventions appear effective for treating overweight among people with serious mental illness. Further research is needed for evaluating long-term effects of the lifestyle interventions as well as focusing special components of the interventions with especially high user benefit.
-
Literatur
- 1 Mahmood S, Levy D, Vasan R. et al. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. The Lancet 2014; 383: 999-1008
- 2 Schienkiewitz A, Walter U. Glossar. In: Schwartz F. et al. Das Public Health Buch. Gesundheit und Gesundheitswesen. 2.. Auflage. München: Urban & Fischer; 2003: 805-829
- 3 Abel T. Gesundheitsrelevante Lebensstile. In: Maeder C. et al. Gesundheit, Medizin und Gesellschaft: Beiträge zur Soziologie der Gesundheit. Zürich: Seismo-Verlag; 1999: 43-61
- 4 Dunn AL, Anderson RE, Jakicic JM. Life-style physical activity interventions: history, short and long term effects and recommendations. Am J Preven Med 1998; 15: 398-412
- 5 Hackshaw A, Morris JK, Boniface S. et al. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ 2018; 360: j5855
- 6 Wippermann C. Lebensstile und Milieus: Einflüsse auf die Gesundheit. In: Schumpelick V, Vogel B. Hrsg. Volkskrankheiten. Freiburg im Breisgau: Herder; 2009: 143-156
- 7 Compton MT, Daumit GL, Druss BG. Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: a preventive perspective. Harv Rev Psychiatry 2006; 14: 212-222
- 8 Richardson CR, Faulkner G, McDevitt J. et al. Integrating physical activity into mental health services for persons with serious mental illness. Psychiatric Services 2005; 56: 324-331
- 9 American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists. Consensus development conference on antipsychotic drugs and obesity and diabetes. Journal of Clinical Psychiatry 2004; 65: 267-272
- 10 Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Archives of General Psychiatry 2011; 68: 609-616
- 11 Newcomer JW, Wieden PJ, Buchanan RW. Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. Journal of Clinical Psychiatry 2013; 74: 1108-1120
- 12 Dickerson FB, Brown CH, Kreyenbuhl JA. et al. Obesity among individuals with serious mental illness. Acta Psychiatr Scand 2006; 113: 306-313
- 13 Allison DB, Newcomer JW, Dunn AL. et al. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med 2009; 36: 341-350
- 14 Daumit GL, Clark JM, Steinwachs DM. et al. Prevalence and correlates of obesity in a community sample of individuals with severe and persistent mental illness. J Nerv Ment Dis 2003; 191: 799-805
- 15 Leucht S, Burkard T, Henderson J. et al. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007; 116: 317-333
- 16 Deutsche Gesellschaft für Adipositas. BMI Klassifikation. (nach WHO, 2000). Im Internet unter: http://www.adipositas-gesellschaft.de/index.php?id=39 (Stand: 21.02.2018)
- 17 Leucht S, Corves C, Arbter D. et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a metaanalysis. Lancet 2009; 373: 31-41
- 18 Holt RI, Peveler RC. Association between antipsychotic drugs and diabetes. Diabetes Obes Metab 2006; 8: 125-135
- 19 Bushe C, Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry 2004; 47: 67-71
- 20 McIntyre RS, Konarski JZ, Misener VL. et al. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005; 17: 83-93
- 21 van Winkel R, De Hert M, Van Eyck D. et al. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J Clin Psychiatry 2006; 67: 1493-1500
- 22 Barnett AH, Mackin P, Chaudhry I. et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 2007; 21: 357-373
- 23 van Winkel R, De Hert M, Van Eyck D. et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008; 10: 342-348
- 24 Regenold WT, Thapar RK, Marano C. et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002; 70: 19-26
- 25 De Hert M, Mauri M, Shaw K. et al. The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology. Int J Methods Psychiatr Res 2010; 19: 195-210
- 26 De Hert M, van Winkel R, Van Eyck D. et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health 2006; 2: 14
- 27 Arroyo C, Hu FB, Ryan LM. et al. Depressive symptoms and risk of type 2 diabetes in women. Diabetes Care 2004; 27: 129-133
- 28 Brown LC, Majumdar SR, Newman SC. et al. History of depression increases risk of type 2 diabetes in younger adults. Diabetes Care 2005; 28: 1063-1067
- 29 Carnethon MR, Kinder LS, Fair JM. et al. Symptoms of depression as a risk factor for incident diabetes: findings from the National Health and Nutrition Examination Epidemiologic Follow-up Study, 1971–1992. Am J Epidemiol 2003; 158: 416-423
- 30 Eaton WW, Armenian H, Gallo J. et al. Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care 1996; 19: 1097-1102
- 31 Everson-Rose SA, Meyer PM, Powell LH. et al. Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care 2004; 27: 2856-2862
- 32 Golden SH, Williams JE, Ford DE. et al. Depressive symptoms and the risk of type 2 diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2004; 27: 429-435
- 33 Kawakami N, Takatsuka N, Shimizu H. et al. Depressive symptoms and occurrence of type 2 diabetes among Japanese men. Diabetes Care 1999; 22: 1071-1076
- 34 Palinkas LA, Lee PP, Barrett-Connor E. A prospective study of type 2 diabetes and depressive symptoms in the elderly: the Rancho Bernardo Study. Diabet Med 2004; 21: 1185-1191
- 35 van den Akker M, Schuurman A, Metsemakers J. et al. Is depression related to subsequent diabetes mellitus?. Acta Psychiatr Scand 2004; 110: 178-183
- 36 Hennekens CH, Hennekens AR, Hollar D. et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150: 1115-1121
- 37 Osborn DP, Levy G, Nazareth I. et al. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s General Practice Research Database. Arch Gen Psychiatry 2007; 64: 242-249
- 38 Goff DC, Sullivan LM, McEvoy JP. et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005; 80: 45-53
- 39 Kisely S, Campbell LA, Wang Y. Treatment of ischaemic heart disease and stroke in individuals with psychosis under universal healthcare. Br J Psychiatry 2009; 195: 545-550
- 40 Kisely S, Smith M, Lawrence D. et al. Inequitable access for mentally ill patients to some medically necessary procedures. CMAJ 2007; 176: 779-784
- 41 Bresee LC, Majumdar SR, Patten SB. et al. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res 2010; 117: 75-82
- 42 Lin HC, Hsiao FH, Pfeiffer S. et al. An increased risk of stroke among young schizophrenia patients. Schizophr Res 2008; 101: 234-241
- 43 Curkendall SM, Mo J, Glasser DB. et al. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry 2004; 65: 715-720
- 44 Lin HC, Tsai SY, Lee HC. Increased risk of developing stroke among patients with bipolar disorder after an acute mood episode: a six-year Follow-up study. J Affect Disord 2007; 100: 49-54
- 45 Millar H. Management of physical health in schizophrenia: a stepping stone to treatment success. Eur Neuropsychopharmacol 2008; 18: S121-128
- 46 WHO. Premature death among people with severe mental disorders. Genf: 2007
- 47 Jayatilleke N. Contributions of specific causes of death to lost life expectancy in severe mental illness. European Psychiatry 2017; 43: 109-115
- 48 Prince M, Patel V, Saxena S. et al. No health without mental health. Lancet 2007; 370: 859-877
- 49 Teychenne M, Ball K, Salmon J. Physical activity and likelihood of depression in adults: a review. Prev Med 2008; 46: 397-411
- 50 Jacka FN, Pasco JA, Mykletun A. et al. Association of western and traditional diets with depression and anxiety in women. Am J Psychiatry 2010; 167: 305-311
- 51 Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine 2009; 6: e1000097
- 52 Cochrane Deutschland, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Bewertung von systematischen Übersichtsarbeiten: ein Manual für die Leitlinienerstellung. 1.. Auflage. Institut für Medizinisches Wissensmanagement; 2017
- 53 Shea BJ, Bouter LM, Peterson J. et al. External validation of a measurement tool to assess systematic reviews (AMSTAR). PloS One 2007; 2: e1350
- 54 The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0: TheCochraneCollaboration. 2011. [cited 2016 22.03.2016]. Available from: http://handbook.cochrane.org/chapter_8/table_8_5_a_the_cochrane_collaborations_tool_for_assessing.htm
- 55 Bruins J, Jörg F, Bruggeman R. et al. The Effects of Lifestyle Interventions on (Long-Term) Weight Management, Cardiometabolic Risk and Depressive Symptoms in People with Psychotic Disorders: A Meta-Analysis. PLoS ONE 2014; 9 e112276. DOI: https://doi.org/10.1371/journal.pone.0112276.
- 56 Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials. Schizophr Res 2012; 140: 159-168
- 57 Bonfioli E, Berti L, Goss C. et al. Health promotion lifestyle interventions for weight management in psychosis: A systematic review and meta- analysis of randomised controlled trials. BMC Psychiatry 2012; 12: 2-12
- 58 Álvarez-Jiménez M, Hetrick S, González-Blanch C. et al. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. The British Journal of Psychiatry 2008; 193: 101-107
- 59 Fernández-San M, López M, Masa-Font R. et al. The effectiveness of lifestyle interventions to reduce cardiovascular risk in patients with severe mental disorders: meta-analysis of intervention studies. Community Ment Health J 2014; 50: 81-95
- 60 Faulkner G, Soundy AA, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatrica Scandinarvica 2003; 108: 324-332
- 61 Green CA, Yarborough BJ, Leo MC. et al. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry 2015; 172: 71-81
- 62 Gillhoff K, Gaab J, Emini L. et al. Effects of a multimodal lifestyle intervention on body mass index in patients with bipolar disorder: a randomized controlled trial. Prim Care Companion J Clin Psychiatry 2010 12. PCC.09m00906
- 63 Masa-Font R, Fernández-San M, López LM. et al. The effectiveness of a program of physical activity and diet to modify cardiovascular risk factors in patients with severe mental illness after 3-month Follow-up: CAPiCOR randomized clinical trial. European Psychiatry 2015; 30: 1028-1036
- 64 Naslund J, Whiteman K, McHugo G. et al. Lifestyle interventions for weight loss among overweight and obese adults with serious mental illness: A systematic review and meta-analysis. Gen Hosp Psychiatry 2017; 47: 83-102
- 65 National Institute for Health and Care Excellence. Guideline „Psychosis and schizophrenia in adults: prevention and management“. 2014
- 66 Scottish Intercollegiate Guidelines Network. Guideline „Management of schizophrenia“. 2013
- 67 Soundy A, Freeman P, Stubbs B. et al. The transcending benefits of physical activity for individuals with schizophrenia: A systematic review and meta-ethnography. Psychiatry Res 2014; 220: 11-19
- 68 Farholm A, Sorensen M. Motivation for physical activity and exercise in severe mental illness: A systematic review of intervention studies. Int J Ment Health Nursing 2016; 25: 194-205
- 69 Firth J, Rosenbaum S, Stubbs B. et al. Motivating factors and barriers towards exercise in severe mental illness: a systematic review and meta-analysis. Psychol Med 2016; 46: 2869-2881
- 70 Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN). S3-Leitlinie Psychosoziale Therapien bei schweren psychischen Erkrankungen. 1. Update. Springer; 2018. in Druck
- 71 Häfner S, Wolff-Menzler C, Schulz M. et al. Diagnosis of Metabolic Risk Factors in Psychiatric Inpatients. Psychiat Prax 2016; 43: 312-317
- 72 Fink A, Cieslak S, Rosenbach F. Non-Pharmacological Interventions for the Prevention of Weight Gain in Schizophrenic Patients Treated with Antipsychotic Medication Systematic Review and Meta-Analysis. Psychiat Prax 2015; 42: 359-369
- 73 Krausz RM. Die systemische und die subjektive Seite der Schizophrenie oder wie weit weg sind wir von einer patientenorientierten Psychiatrie?. Psychiat Prax 2017; 44: 188-189
- 74 Gühne U, Weinmann S, Becker T. et al. Die S3-Leitlinie „Psychosoziale Therapien bei schweren psychischen Erkrankungen“ – nach dem Update ist vor dem Update. Psychiat Prax 2018; 45: 119-121